Literature DB >> 3829052

Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer.

A Lichtenstein.   

Abstract

The antitumor effects of the streptococcal preparation OK-432 were analyzed in a murine ovarian teratocarcinoma (MOT) model. Administration of OK-432 i.p. prevented tumor outgrowth in 75% of mice challenged with 10(3) MOT cells i.p. 24 h previously. Treatment was less successful in mice challenged with 10(4) or 10(5) cells, preventing tumor growth in 25% of the former and only 5% of the latter group. Tumor-challenged mice cured by injections of OK-432 were not rendered resistant to a subsequent challenge with 10(3) MOT cells 75 days after initial treatment. Only the i.p. route of administration was effective as i.v. OK-432 did not prolong survival of tumor-challenged mice. An antitumor response was detected as early as 24 h after i.p. treatment. This correlated temporally with an influx of neutrophils into the peritoneal cavity. Peritoneal cells obtained between 6 and 24 h after treatment were capable of lysing MOT targets in vitro. A single cell cytotoxicity assay demonstrated that peritoneal neutrophils, elicited by i.p. injection of OK-432, could bind to and lyse MOT targets. These data indicate that OK-432 is effective against small tumor cell inocula in this murine model of ovarian cancer and, furthermore, that the neutrophilic response into the peritoneal cavity plays a role in tumor rejection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829052     DOI: 10.1007/bf00205596

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Studies on a transplantable teratoma of the mouse.

Authors:  E FEKETE; M A FERRIGNO
Journal:  Cancer Res       Date:  1952-06       Impact factor: 12.701

2.  Studies of the induction and expression of T cell mediated immunity. VI. Heterogeneity of lytic efficiency exhibited by isolated cytotoxic T lymphocytes prepared from highly enriched populations of effector-target conjugates.

Authors:  E A Grimm; B Bonavida
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

3.  Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes.

Authors:  M Saito; T Ebina; M Koi; T Yamaguchi; Y Kawade; N Ishida
Journal:  Cell Immunol       Date:  1982-03-15       Impact factor: 4.868

4.  Anti-tumor effect of inflammatory neutrophils: characteristics of in vivo generation and in vitro tumor cell lysis.

Authors:  A Lichtenstein; J Kahle
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

5.  Enhancement of antileukemic effect in combination of 5-fluorouracil and OK-432.

Authors:  S Koshimura; K Ryoyama
Journal:  Cancer Treat Rep       Date:  1977 Jan-Feb

6.  Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.

Authors:  A K Lichtenstein; J Kahle; J Berek; J Zighelboim
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

7.  Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.

Authors:  C P Vanhaelen; R I Fisher
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

8.  Activation of macrophage function by intraperitoneal administration of the streptococcal antitumor agent OK-432.

Authors:  T Kawaguchi; M Suematsu; H M Koizumi; H Mitsui; S Suzuki; T Matsuno; H Ogawa; K Nomoto
Journal:  Immunopharmacology       Date:  1983-10

9.  Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes.

Authors:  A Uchida; M Micksche; T Hoshino
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells.

Authors:  A Uchida; M Micksche
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

View more
  5 in total

1.  Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.

Authors:  H Fukui; C W Reynolds; B Lenz; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer.

Authors:  K Furukawa; E Lotzová; R S Freedman; J B Bowen; C L Edwards; J T Wharton
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Augmentation of antimetastatic effect on Lewis lung carcinoma (3LL) in C57BL/6 mice by priming with Lactobacillus casei.

Authors:  T Matsuzaki; Y Shimizu; T Yokokura
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

4.  Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation.

Authors:  M Katano; H Yamamoto; T Mizoguchi; T Hisatsugu
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer.

Authors:  Li Li; Wei Wang; Hong Pan; Ge Ma; Xinyi Shi; Hui Xie; Xiaoan Liu; Qiang Ding; Wenbin Zhou; Shui Wang
Journal:  J Transl Med       Date:  2017-01-31       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.